schizophrenia
| 5 min read
A first-in-class synaptic regenerative approach shows promise across multiple neurodegenerative and neuropsychiatric diseases.
| 4 min read
Vertex-Enlaza autoimmune drugs, DNA-wrapped CRISPR, HHS staff demand Kennedy’s resignation, and more lead the news this week.
| 2 min read
The therapy crosses the blood-brain barrier after peripheral injection and delivers behavioral improvements that last up to seven days.
| 4 min read
The therapy met its primary endpoints in two Phase 3 studies and offers a new approach for the tens of millions of people living with the psychiatric condition.
| 4 min read
Stimulating dopamine neurons in adolescent mice rescued cognitive deficits associated with future development of neuropsychiatric disorders.
| 10+ min read
A new type of drug for schizophrenia could finally be approved in September. Others may not be far behind.
| 7 min read
With a star-shaped drug delivery platform that can stay in the stomach for a week or more, researchers hope to improve medication compliance and overall health.
| 4 min read
Researchers identified schizophrenia risk genes that mediate placental, rather than brain, function, revealing new insight into the disease’s developmental origins.
| 10+ min read
Researchers around the world are on a mission to bank biological samples from millions of people. So far, these efforts have disclosed the effects of arsenic exposure on the genome, supported development of early cancer diagnostics, and even revealed the ideal timing for COVID-19 boosters.
| 4 min read
A newly developed drug stabilizes dopamine and serotonin levels using a novel mechanism. It effectively treats psychosis in patients with schizophrenia, and researchers are testing its efficacy for Parkinson’s disease as well.
